{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:39:11Z","timestamp":1761007151241,"version":"build-2065373602"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.soc.2019.02.011","type":"journal-article","created":{"date-parts":[[2019,4,15]],"date-time":"2019-04-15T17:33:42Z","timestamp":1555349622000},"page":"481-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of Surgery in Combination with Immunotherapy"],"prefix":"10.1016","volume":"28","author":[{"given":"Nicholas D.","family":"Klemen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mackenzie L.","family":"Shindorf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard M.","family":"Sherry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.soc.2019.02.011_bib1","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: the first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"25","key":"10.1016\/j.soc.2019.02.011_bib2","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N\u00a0Engl J Med"},{"issue":"5796","key":"10.1016\/j.soc.2019.02.011_bib3","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.soc.2019.02.011_bib4","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.soc.2019.02.011_bib5","first-page":"JCO667220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","author":"Goff","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2019.02.011_bib6","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2019.02.011_bib7","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2019.02.011_bib8","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2019.02.011_bib9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.soc.2019.02.011_bib10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.soc.2019.02.011_bib11","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1245\/s10434-012-2398-z","article-title":"Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I)","volume":"19","author":"Howard","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"13","key":"10.1016\/j.soc.2019.02.011_bib12","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1245\/s10434-017-6072-3","article-title":"Long-term survival after complete surgical resection and adjuvant immunotherapy for distant melanoma metastases","volume":"24","author":"Faries","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.soc.2019.02.011_bib13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ni.3682","article-title":"\u201cFinal common pathway\u201d of human cancer immunotherapy: targeting random somatic mutations","volume":"18","author":"Tran","year":"2017","journal-title":"Nat Immunol"},{"issue":"7457","key":"10.1016\/j.soc.2019.02.011_bib14","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"6184","key":"10.1016\/j.soc.2019.02.011_bib15","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","article-title":"Cancer immunotherapy based on mutation-specific CD4+ T\u00a0cells in a patient with epithelial cancer","volume":"344","author":"Tran","year":"2014","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.soc.2019.02.011_bib16","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2019.02.011_bib17","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semradonc.2005.12.008","article-title":"Treatment of oligometastases after successful immunotherapy","volume":"16","author":"Yang","year":"2006","journal-title":"Semin Radiat Oncol"},{"issue":"4","key":"10.1016\/j.soc.2019.02.011_bib18","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1464-410X.2009.08490.x","article-title":"Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma","volume":"104","author":"Daliani","year":"2009","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.soc.2019.02.011_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/jso.24916","article-title":"Metastasectomy following incomplete response to high-dose interleukin-2","volume":"117","author":"Hughes","year":"2017","journal-title":"J\u00a0Surg Oncol"},{"issue":"9","key":"10.1016\/j.soc.2019.02.011_bib20","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1245\/s10434-013-2999-1","article-title":"Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma","volume":"20","author":"Gyorki","year":"2013","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.soc.2019.02.011_bib21","unstructured":"Bello DM, Panageas KS, Hollmann TJ, et\u00a0al. Outcomes of patients with metastatic melanoma selected for surgery after immunotherapy. Society of Surgical Oncology Annual Cancer Symposium, Abstract 5. Presented Chicago, March 23, 2018."},{"issue":"1","key":"10.1016\/j.soc.2019.02.011_bib22","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1245\/s10434-016-5537-0","article-title":"Metastasectomy following immunotherapy with adoptive cell transfer for patients with advanced melanoma","volume":"24","author":"Klemen","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.soc.2019.02.011_bib23","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.soc.2019.02.011_bib24","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2019.02.011_bib25","doi-asserted-by":"crossref","first-page":"e87705","DOI":"10.1371\/journal.pone.0087705","article-title":"Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab","volume":"9","author":"Tarhini","year":"2014","journal-title":"PLoS One"},{"issue":"Suppl 13","key":"10.1016\/j.soc.2019.02.011_bib26","doi-asserted-by":"crossref","first-page":"CT181","DOI":"10.1158\/1538-7445.AM2018-CT181","article-title":"Abstract CT181: Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma","volume":"78","author":"Huang","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.soc.2019.02.011_bib27","doi-asserted-by":"crossref","unstructured":"Rozeman E.A. Abstract (Neo-)adjuvant ipilimumab + nivolumab (IPI+ NIVO) in palpable stage 3 melanoma \u2013 updated relapse free survival (RFS) data from the OpACIN trial and first biomarker analyses. ESMO Annals of Oncology Abstract Book of 42nd ESMO Congress; 2017.","DOI":"10.1093\/annonc\/mdx377.008"},{"issue":"21","key":"10.1016\/j.soc.2019.02.011_bib28","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N\u00a0Engl J Med"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719300250?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320719300250?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:03:24Z","timestamp":1760961804000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320719300250"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1055320719300250"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2019.02.011","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Surgery in Combination with Immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2019.02.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}